StockData
Cerenome, Inc. logo

Cerenome, Inc. (CNSY) stock

CNSYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 8/3071% below fair value
$0.63−0.08 (-11.82%)

Close on Nov 17, 2026Market cap $4.78MP/E –Yield –

Cerenome operating margin

Operating margin is operating income as a percentage of revenue.

Cerenome's operating margin for the twelve months ending Jun 30, 2026 was -628.1%. For fiscal 2025 it was -293.5%, against -252.3% the year before. The highest annual figure on record is -238.7% in fiscal 2018.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-293.5%−41.1
FY2024Dec 31, 2024-252.3%+18.8
FY2023Dec 31, 2023-271.1%−32.5
FY2018Dec 31, 2018-238.7%+530.5
FY2017Dec 31, 2017-769.2%−345.9
FY2016Dec 31, 2016-423.2%−107.3
FY2015Dec 31, 2015-316.0%+338.9
FY2014Dec 31, 2014-654.9%−224.1
FY2013Dec 31, 2013-430.8%−104.5
FY2012Dec 31, 2012-326.3%+42.1
FY2011Dec 31, 2011-368.4%−61.6
FY2010Dec 31, 2010-306.8%+62.3
FY2009Dec 31, 2009-369.1%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-2203.6%−2093.0
Q1 FY2026Mar 31, 2026-692.5%−358.6
Q4 FY2025Dec 31, 2025-420.0%−143.8
Q3 FY2025Sep 30, 2025-320.8%−59.9
Q2 FY2025Jun 30, 2025-110.6%+178.4
Q1 FY2025Mar 31, 2025-333.9%−137.2
Q4 FY2024Dec 31, 2024-276.2%+31.9
Q3 FY2024Sep 30, 2024-260.9%−126.6
Q2 FY2024Jun 30, 2024-289.1%+306.3
Q1 FY2024Mar 31, 2024-196.7%+351.6
Q1 FY2019Mar 31, 2019-308.1%+621.9
Q4 FY2018Dec 31, 2018-134.3%+441.6
Q1 FY2018Mar 31, 2018-595.3%+610.9
Q4 FY2017Dec 31, 2017-548.3%−303.5
Q3 FY2017Sep 30, 2017-930.0%−273.8
Q2 FY2017Jun 30, 2017-576.0%−23.2
Q1 FY2017Mar 31, 2017-1206.3%–
Q4 FY2016Dec 31, 2016-244.9%–
Q3 FY2016Sep 30, 2016-656.2%–
Q2 FY2016Jun 30, 2016-552.8%–

More Cerenome figures

See a number that looks wrong?